Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|Independent Lab Verified|≥98% Purity Guarantee|Shipped Within 24hrs|Batch-Specific COAs|International Shipping|North American Made|Free Shipping $149 USD+|New: Research Bundles Available|
All Comparisons

BPC-157 vs GHK-Cu

Side-by-side comparison of evidence, mechanisms, dosing, safety, and regulatory status.

BPC-157: CGHK-Cu: F
AttributeBPC-157GHK-Cu
CategoryHealing & RecoverySkin & Tissue Repair
Evidence RatingC — Phase I–II Clinical TrialsF — No Regulatory Activity
Clinical StatusResearch-only / No approved human indication. Phase I oral safety trial completed; Phase II UC trial underway.Available in cosmetic formulations; no drug approval
MechanismBPC-157 acts through multiple overlapping pathways. It promotes angiogenesis by upregulating VEGFR2 and VEGF expression, and activates nitric oxide synthesis via the Src kinase-caveolin-1 pathway and Akt-eNOS axis. It engages ERK1/2 signaling, activating c-Fos, c-Jun, and EGR-1 transcription factors...GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. It stimulates collagen, elastin, and glycosaminoglycan synthesis, modulates metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), attracts i...
Half-Life~15 min IV (animal data); oral activity persists 24+ hours~30 minutes plasma
BioavailabilityIM: 15-19% (rats), 45-51% (dogs); resistant to stomach acid degradation—
Molecular Weight~1419.5 g/mol~403.9 g/mol
WADA StatusProhibitedNot Listed
Dosing200–600 mcg/day SC; oral doses studied at 1–6 mg in clinical trials, Once daily (Subcutaneous (preferred), Intramuscular, or Oral)SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area, SC: Once daily; Topical: 1–2x daily (Subcutaneous, Topical (cream/serum), or Intradermal (microneedling))
Key Use Cases
  • Injury Recovery
  • Gut Health
  • Skin Health
  • Anti-Aging
  • Wound Healing
Safety Concerns
  • No completed randomized controlled human clinical trials for safety assessment
  • Preclinical safety studies across multiple species found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 not achieved; no teratogenic, genotoxic, or anaphylactic effects in necropsy/histopathology
  • FDA previously classified BPC-157 as Category 2 (significant safety concerns); removed from Category 2 on April 15, 2026. PCAC review pending July 2026 to determine compounding eligibility. FDA noted insufficient human safety data and potential immunogenicity risks.
  • Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520)
  • Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin
  • Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Contraindications
  • Pregnancy and breastfeeding (no safety data)
  • Active cancer or history of cancer (theoretical concern due to potent angiogenesis promotion; mechanistic overlap with tumor vascularization)
  • Individuals on anticoagulants (BPC-157 affects clotting and vessel constriction resolution)
  • Autoimmune conditions (immunogenicity risk noted by FDA)
  • Copper sensitivity, Wilson disease, or Menkes disease (copper overload conditions)
  • Active skin infections at application site
  • Pregnancy and breastfeeding (safety not established)
  • Active cancer without medical clearance
Regulatory (US)Not FDA-approved. Removed from Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026 to determine compounding eligibility. Previously prohibited from compounding under Category 2 since September 2023. WADA-banned.Available as a cosmetic ingredient (Copper Tripeptide-1). Not FDA-approved as a drug. Removed from FDA Category 2 on April 15, 2026 after HHS Secretary Kennedy directed withdrawal of nominations. PCAC review scheduled July 23-24, 2026. No IND application filed for injectable use.

Shop BPC-157

View BPC-157 Product

Shop GHK-Cu

View GHK-Cu Product

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

All ComparisonsBrowse Catalog

Your Cart

Your cart is empty

Browse our catalog to add research compounds.